Camurus Q3 2024 Interim Report

Camurus has reported a strong third quarter in 2024, marked by robust financial progress and significant advancements across its business segments. The company's flagship products, Buvidal and Brixadi, experienced continued sales growth, culminating in the highest financial results to date, excluding one-time revenue impacts. This performance highlights Camurus' solid operational base and market presence.

Fredrik Tiberg, President and CEO of Camurus, lauded the company's achievements, noting the positive financial trajectory and excellent performance across its diverse business lines. He emphasized the growth in sales of Buvidal and Brixadi, which substantially contributed to the quarter's successful financial outcomes. Tiberg also highlighted the pipeline's progress, particularly the encouraging Phase 3 results from the ACROINNOVA 2 study. These results confirmed the long-term safety and efficacy of CAM2029 in treating patients with acromegaly, a significant milestone for the company's clinical development efforts.

In addition to the progress with CAM2029 for acromegaly, Camurus advanced its clinical studies for other indications. These include ongoing studies of CAM2029 for treating neuroendocrine tumors and polycystic liver disease, demonstrating the company's commitment to expanding its therapeutic reach. In the United States, the FDA continued to review Camurus' new drug application for CAM2029 as a treatment for acromegaly. Although a Complete Response Letter was issued after the quarter, it related solely to a cGMP-inspection at a third-party manufacturing site, with an inspection classification pending. This indicates that the review process for CAM2029 is progressing, albeit with some regulatory hurdles to address.

Camurus invited financial analysts and media to a telephone conference and presentation of the third quarter results. This event provided a platform for discussing the company’s financial performance and ongoing projects in greater detail, allowing stakeholders to gain deeper insights into Camurus' operations and future outlook.

Camurus, a Swedish biopharmaceutical company, is known for its innovative approach to developing and commercializing medicines for severe and chronic conditions. The company's proprietary FluidCrystal® drug delivery technologies form the backbone of its new drug products, which have the potential to be best-in-class. Camurus’ clinical pipeline addresses a range of conditions, including dependence, pain, cancer, and endocrine diseases, through both in-house development and partnerships with international pharmaceutical firms. The company's shares are traded on Nasdaq Stockholm under the ticker CAMX.

The third quarter of 2024 has solidified Camurus' position as a growing leader in the biopharmaceutical industry, with significant advancements in product sales and clinical development. The continued success of Buvidal and Brixadi, along with the promising pipeline progress, underscores the company's potential for sustained growth and its commitment to addressing unmet medical needs. As Camurus navigates regulatory processes and advances its clinical programs, the company remains focused on delivering innovative treatments to improve patient outcomes worldwide.